ADAPTIN BIO, INC.

ADAPTIN BIO, INC. develops and commercializes products using a novel technology designed to improve the delivery of drugs and other compounds to the brain and other tissues for various medical conditions. The company's core technology originated from research conducted by the Department of Neurosurgery at Duke University and was licensed by ADAPTIN BIO, INC. in 2023. The company operates as an "emerging growth company" under the Jumpstart Our Business Startups Act, or JOBS Act. This status allows ADAPTIN BIO, INC. to take advantage of certain exemptions from reporting requirements. These exemptions include not being required to have its independent registered public accounting firm audit internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations for executive compensation in periodic reports and annual reports on Form 10-K, and exemptions from non-binding advisory votes on executive compensation and stockholder approval of golden parachute payments not previously approved. Additionally, as an emerging growth company, ADAPTIN BIO, INC. can delay adopting new or revised accounting standards until they apply to private companies. The company's emerging growth company status will conclude upon the earliest of: the fifth anniversary of the first sale of its common equity securities under an effective registration statement; the last day of the fiscal year when it exceeds $1.235 billion in annual gross revenues; qualifying as a "large accelerated filer" with at least $700 million of equity securities held by non-affiliates; or issuing more than $1 billion in non-convertible debt securities within any three-year period.